Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/2700
Title: | Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-NaЇve Advanced Non-small Cell Lung Cancer |
Authors: | Готько, Євген Степанович Mary, E. R. |
Keywords: | Non-small cell lung cancer, Paclitaxel poliglumex, PPX, CT-2103, PS 2, Toxicity |
Issue Date: | Jul-2008 |
Publisher: | Journal of Thoracic Oncology |
Series/Report no.: | Volume 3,;Number 7 |
Abstract: | Background: Patients with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) have limited life expectancies and decreased tolerance for drug-induced toxicities. Current treatment guidelines indicate that PS 2 patients benefit from systemic therapy. Further refinement of treatment in these patients requires reduction of treatment-associated toxicities while maintaining or improving efficacy. Paclitaxel poliglumex (PPX), a macromolecular polymer– drug conjugate of paclitaxel and poly-Lglutamic acid, may enhance the therapeutic index of paclitaxel. |
Type: | Text |
Publication type: | Стаття |
URI: | https://dspace.uzhnu.edu.ua/jspui/handle/lib/2700 |
ISSN: | 1556-0864 |
Appears in Collections: | Наукові публікації кафедри радіології та онкології |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Randomized_Phase_III_Trial_Comparing_Single_Agent.7.pdf | Основна стаття | 216.76 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.